» Articles » PMID: 31973229

Extracellular Vesicles, A Possible Theranostic Platform Strategy for Hepatocellular Carcinoma-An Overview

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Jan 25
PMID 31973229
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third highest cause of mortality from cancer, largely because of delays in diagnosis. There is currently no effective therapy for advanced stage HCC, although sorafenib, the standard treatment for HCC, systemic therapy (including tyrosine kinase inhibitors and anti-angiogenesis agents), and more recently, immunotherapy, have demonstrated some survival benefit. The measurement and modification of extracellular vesicle (EVs) cargoes-composed of nucleic acids, including miRNAs, proteins, and lipids-holds great promise for future HCC diagnosis, prognosis, and treatment. This review will provide an overview of the most recent findings regarding EVs in HCC, and the possible future use of EVs as "liquid biopsy"-based biomarkers for early diagnosis and as a vehicle for targeted drug-delivery.

Citing Articles

Extracellular vesicles in hepatocellular carcinoma: unraveling immunological mechanisms for enhanced diagnosis and overcoming drug resistance.

Su L, Yue Y, Yan Y, Sun J, Meng L, Lu J Front Immunol. 2024; 15:1485628.

PMID: 39530097 PMC: 11550962. DOI: 10.3389/fimmu.2024.1485628.


Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression.

Zhang Y, Wang C, Li J Exp Hematol Oncol. 2024; 13(1):64.

PMID: 38951845 PMC: 11218091. DOI: 10.1186/s40164-024-00532-4.


Extracellular vesicles as potential biomarkers for diagnosis and recurrence detection of hepatocellular carcinoma.

Juratli M, Pollmann N, Oppermann E, Mohr A, Roy D, Schnitzbauer A Sci Rep. 2024; 14(1):5322.

PMID: 38438456 PMC: 10912302. DOI: 10.1038/s41598-024-55888-8.


Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.

Pallozzi M, Di Tommaso N, Maccauro V, Santopaolo F, Gasbarrini A, Ponziani F Cancers (Basel). 2022; 14(19).

PMID: 36230554 PMC: 9559710. DOI: 10.3390/cancers14194631.


Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma.

Yao M, Yang J, Wang D, Wang L, Chen Y, Yao D World J Clin Cases. 2022; 10(11):3321-3333.

PMID: 35611205 PMC: 9048543. DOI: 10.12998/wjcc.v10.i11.3321.


References
1.
Meldolesi J . Exosomes and Ectosomes in Intercellular Communication. Curr Biol. 2018; 28(8):R435-R444. DOI: 10.1016/j.cub.2018.01.059. View

2.
Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T . Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018; 37(1):52. PMC: 5846230. DOI: 10.1186/s13046-018-0677-7. View

3.
Li Y, Zhao J, Yu S, Wang Z, He X, Su Y . Extracellular Vesicles Long RNA Sequencing Reveals Abundant mRNA, circRNA, and lncRNA in Human Blood as Potential Biomarkers for Cancer Diagnosis. Clin Chem. 2019; 65(6):798-808. DOI: 10.1373/clinchem.2018.301291. View

4.
Tang J, Li Y, Liu K, Zhu Q, Yang W, Xiong L . Exosomal miR-9-3p suppresses HBGF-5 expression and is a functional biomarker in hepatocellular carcinoma. Minerva Med. 2017; 109(1):15-23. DOI: 10.23736/S0026-4806.17.05167-9. View

5.
Kosgodage U, Mould R, Henley A, Nunn A, Guy G, Thomas E . Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer. Front Pharmacol. 2018; 9:889. PMC: 6099119. DOI: 10.3389/fphar.2018.00889. View